Effect of antiviral therapy for HCV on lipid levels

Antiviral Therapy

Volumn 22, Issue 1, 2017, Pages 81-88

  Mauss, Stefan ^a   Berger, Florian ^a   Wehmeyer, Malte H ^b   Ingiliz, Patrick ^c   Hueppe, Dietrich ^d   Lutz, Thomas ^e   Simon, Karl G ^f   Schewe, Knud ^g   Rockstroh, Juergen K ^h   Baumgarten, Axel ^c   Christensen, Stefan ⁱ  

^a Center for HIV and Hepatogastroenterology   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c Center for Infectiology (CIB)   (Germany)

^d Practice for Gastroenterology   (Germany)

^e Infektiologikum   (Germany)

^f Gastroenterology Practice   (Germany)

^g Infektionsmedizinisches Centrum Hamburg   (Germany)

^h UNIVERSITY HOSPITAL BONN   (Germany)

ⁱ CIM Infectious diseases   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; DACLATASVIR; DASABUVIR PLUS OMBITASVIR PLUS PARITAPREVIR PLUS RITONAVIR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LEDIPASVIR PLUS SOFOSBUVIR; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PEGINTERFERON; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; TRIACYLGLYCEROL; VIRUS RNA; ANTIVIRUS AGENT; BIOLOGICAL MARKER;

ADULT; ANTIRETROVIRAL THERAPY; ANTIVIRAL THERAPY; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHRONIC HEPATITIS C; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATIONAL STUDY; DRUG EFFECT; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPID ANALYSIS; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MIXED INFECTION; PROSPECTIVE STUDY; RISK FACTOR; SUSTAINED VIROLOGIC RESPONSE; BLOOD; CLINICAL TRIAL; COMBINATION DRUG THERAPY; COMORBIDITY; DRUG EFFECTS; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C; LIPID METABOLISM; MULTICENTER STUDY; TREATMENT OUTCOME; VIROLOGY; VIRUS LOAD;

ADULT; ANTIVIRAL AGENTS; BIOMARKERS; COINFECTION; COMORBIDITY; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HIV INFECTIONS; HUMANS; LIPID METABOLISM; LIPIDS; MALE; MIDDLE AGED; RISK FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 85015937090     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP3094     Document Type: Article

References (17)

1. Aizawa Y, Seki N, Nagano T, Abe H. Chronic hepatitis C virus infection and lipoprotein metabolism. World J Gastroenterol 2015; 21:10299-10313.
2. Albecka A, Belouzard S, Op de Beeck A, et al. Role of lowdensity lipoprotein receptor in the hepatitis C virus life cycle. Hepatology 2012; 55:998-1007.
3. Merz A, Long G, Hiet MS, et al. Biochemical and morphological properties of hepatitis C virus particles and determination of their lipidome. J Biol Chem 2011; 286:3018-3032.
4. Scholtes C, Ramière C, Rainteau D, et al. High plasma level of nucleocapsid-free envelope glycoprotein-positive lipoproteins in hepatitis C patients. Hepatology 2012; 56:39-48.
5. André P, Komurian-Pradel F, Deforges S, et al. Characterization of low- and very-low-density hepatitis C virus RNA-containing particles. J Virol 2002; 76:6919-6928.
6. Liu S, McCormick KD, Zhao W, Zhao T, Fan D, Wang T. Human apolipoprotein E peptides inhibit hepatitis C virus entry by blocking virus binding. Hepatology 2012; 56:484-491.
7. Hofer H, Bankl HC, Wrba F, et al. Hepatocellular fat accumulation and low serum cholesterol in patients infected with HCV-3a. Am J Gastroenterol 2002; 97:2880-2885.
8. Siagris D, Christofidou M, Theocharis GJ, et al. Serum lipid pattern in chronic hepatitis C: histological and virological correlations. J Viral Hepat 2006; 13:56-61.
9. Lambert JE, Bain VG, Ryan EA, Thomson AB, Clandinin MT. Elevated lipogenesis and diminished cholesterol synthesis in patients with hepatitis C viral infection compared to healthy humans. Hepatology 2013; 57:1697-1704.
10. Mirandola S, Realdon S, Iqbal J, et al. Liver microsomal triglyceride transfer protein is involved in hepatitis C liver steatosis. Gastroenterology 2006; 130:1661-1669.
11. Clark PJ, Thompson AJ, Vock DM, et al. Hepatitis C virus selectively perturbs the distal cholesterol synthesis pathway in a genotype-specific manner. Hepatology 2012; 56:49-56.
12. Younossi ZM, Stepanova M, Estep M, et al. Dysregulation of distal cholesterol biosynthesis in association with relapse and advanced disease in CHC genotype 2 and 3 treated with sofosbuvir and ribavirin. J Hepatol 2016; 64:29-36.
13. Negro F. Facts and fictions of HCV and comorbidities: steatosis, diabetes mellitus, and cardiovascular diseases. J Hepatol 2014; 61:S69-S78.
14. Lee MH, Yang HI, Lu SN, et al. Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study. J Infect Dis 2012; 206:469-477.
15. Meissner EG, Lee YJ, Osinusi A, et al. Effect of sofosbuvir and ribavirin treatment on peripheral and hepatic lipid metabolism in chronic hepatitis C virus, genotype 1-infected patients. Hepatology 2015; 61:790-801.
16. Lange CM, von Wagner M, Bojunga J, et al. Serum lipids in European chronic HCV genotype 1 patients during and after treatment with pegylated interferon-a-2a and ribavirin. Eur J Gastroenterol Hepatol 2010; 22:1303-1307.
17. Younossi ZM, Elsheikh E, Stepanova M, et al. Ledipasvir/sofosbuvir treatment of hepatitis C virus is associated with reduction in serum apolipoprotein levels. J Viral Hepat 2015; 22:977-982.